FDA Clears First AI Tool for 5-Year Breast Cancer Risk Prediction from Mammograms

May 31, 2025

Clairity Breast becomes the first FDA-authorized AI software to predict five-year breast cancer risk using routine mammography images.

Key Details

  • FDA grants de novo authorization to Clairity Breast, developed by Boston-based Clairity.
  • The AI tool analyzes mammogram images for subtle features correlated with future cancer risk.
  • Unlike traditional models, Clairity Breast does not require age or genetic data.
  • The system was trained on millions of mammogram images linked to five-year outcomes.
  • Clairity Breast delivers validated risk scores to radiologists through standard clinical systems.
  • Commercial launch is targeted for the end of 2025.

Why It Matters

This breakthrough FDA authorization marks a new era in preventive oncology by enabling earlier risk identification using only imaging, potentially improving precision prevention and patient outcomes in breast cancer care.

Read more

Ready to Sharpen Your Edge?

Join hundreds of your peers who rely on RadAI Slice. Get the essential weekly briefing that empowers you to navigate the future of radiology.

We respect your privacy. Unsubscribe at any time.